Trenchant Biosystems

Trenchant Biosystems, founded in 2022, is developing scalable, efficient and rapid cell therapy manufacturing technologies and processes to address the lengthy, cumbersome and unreliable nature of current cell and gene therapy (CGT) manufacturing. The company's core innovation reduces CAR-T cell therapy manufacturing time to 2.5 days, a dramatic improvement over conventional multi-week processes. Founded by a team with deep first-hand experience in CGT manufacturing, including over 50 US patents and 200 worldwide in automated cell therapy manufacturing technologies. Trenchant Biosystems is actively seeking manufacturing and technology partnerships with cell and gene therapy companies and CDMOs.